{"schema_version":"secwatch.filing_event.v1","accession":"0001411685-25-000028","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.207575+00:00","generated_at":"2026-05-20T02:36:52.315605+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vistagen updates fasedienol Phase 3 timelines: PALISADE-3 data Q4 2025, PALISADE-4 H1 2026","bullets":["PALISADE-3 topline data remains on track for Q4 2025; PALISADE-4 now expected in H1 2026.","Positive PALISADE-2 results (2023) plus success in either PALISADE-3 or -4 could support NDA submission.","Protocol enhancements include site training, surveillance, and subject selection to replicate PALISADE-2 success.","CEO cites strong patient/physician enthusiasm and growing unmet need in social anxiety disorder."],"urls":{"canonical":"https://secwatch.observer/filing/0001411685-25-000028","json":"https://secwatch.observer/filing/0001411685-25-000028.json","markdown":"https://secwatch.observer/filing/0001411685-25-000028.md","text":"https://secwatch.observer/filing/0001411685-25-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000028/0001411685-25-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000028/vtgn-20250602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:36:52.315605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}